Capture-Based Next-Generation Sequencing Improves the Identification of Immunoglobulin/T-Cell Receptor Clonal Markers and Gene Mutations in Adult Acute Lymphoblastic Leukemia Patients Lacking Molecular Probes

The monitoring of minimal residual disease (MRD) in Philadelphia-negative acute lymphoblastic leukemia (ALL) requires the identification at diagnosis of immunoglobulin/T-cell receptor (Ig/TCR) rearrangements as clonality markers. Aiming to simplify and possibly improve the patients’ initial screening, we designed a capture-based next-generation sequencing (NGS) panel combining the Ig/TCR rearrangement detection with the profiling of relevant leukemia-related genes. The validation of the assay on well-characterized samples allowed us to identify all the known Ig/TCR rearrangements as well as additional clonalities, including rare rearrangements characterized by uncommon combinations of variable, diversity, and joining (V-D-J) gene segments, oligoclonal rearrangements, and low represented clones. Upon validation, the capture NGS approach allowed us to identify Ig/TCR clonal markers in 87% of a retrospective cohort (MRD-unknown within the Northern Italy Leukemia Group (NILG)-ALL 09/00 clinical trial) and in 83% of newly-diagnosed ALL cases in which conventional method failed, thus proving its prospective applicability. Finally, we identified gene variants in 94.7% of patients analyzed for mutational status with the same implemented capture assay. The prospective application of this technology could simplify clonality assessment and improve standard assay development for leukemia monitoring, as well as provide information about the mutational status of selected leukemia-related genes, potentially representing new prognostic elements, MRD markers, and targets for specific therapies.

[1]  K. Stamatopoulos,et al.  Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study , 2019, Leukemia.

[2]  K. Stamatopoulos,et al.  Quality control and quantification in IG/TR next-generation sequencing marker identification: protocols and bioinformatic functionalities by EuroClonality-NGS , 2019, Leukemia.

[3]  K. Stamatopoulos,et al.  Next-generation sequencing of immunoglobulin gene rearrangements for clonality assessment: a technical feasibility study by EuroClonality-NGS , 2019, Leukemia.

[4]  J. Martínez-López,et al.  Minimal Residual Disease Monitoring with Next-Generation Sequencing Methodologies in Hematological Malignancies , 2019, International journal of molecular sciences.

[5]  M. Loh,et al.  Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL. , 2018, Blood.

[6]  J. Soulier,et al.  Mutant JAK3 signaling is increased by loss of wild-type JAK3 or by acquisition of secondary JAK3 mutations in T-ALL. , 2018, Blood.

[7]  M. Brüggemann,et al.  Minimal residual disease in adult ALL: technical aspects and implications for correct clinical interpretation. , 2017, Blood advances.

[8]  K. Stamatopoulos,et al.  High-Throughput Immunogenetics for Clinical and Research Applications in Immunohematology: Potential and Challenges , 2017, The Journal of Immunology.

[9]  J. Trka,et al.  Is Next-Generation Sequencing the way to go for Residual Disease Monitoring in Acute Lymphoblastic Leukemia? , 2017, Molecular Diagnosis & Therapy.

[10]  C. Bloomfield,et al.  High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  K. Stamatopoulos,et al.  Comprehensive translocation and clonality detection in lymphoproliferative disorders by next-generation sequencing , 2017, Haematologica.

[12]  Mikaël Salson,et al.  Vidjil: A Web Platform for Analysis of High-Throughput Repertoire Sequencing , 2016, PloS one.

[13]  F. Mannelli,et al.  Achieving Molecular Remission before Allogeneic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Impact on Relapse and Long-Term Outcome. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[14]  A. Kohlmann,et al.  Mutations of TP53 gene in adult acute lymphoblastic leukemia at diagnosis do not affect the achievement of hematologic response but correlate with early relapse and very poor survival , 2016, Haematologica.

[15]  Alberto Orfao,et al.  Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies. , 2015, Blood.

[16]  C. Desmarais,et al.  IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients. , 2015, Blood.

[17]  A. Palumbo,et al.  Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders , 2014, Leukemia.

[18]  Claude Preudhomme,et al.  Fast multiclonal clusterization of V(D)J recombinations from high-throughput sequencing , 2014, BMC Genomics.

[19]  J. Esteve,et al.  Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  D. Campana,et al.  Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. , 2012, Blood.

[21]  C. Mullighan.  The molecular genetic makeup of acute lymphoblastic leukemia. , 2012, Hematology. American Society of Hematology. Education Program.

[22]  Helga Thorvaldsdóttir,et al.  Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration , 2012, Briefings Bioinform..

[23]  D. Hoelzer,et al.  Modern therapy of acute lymphoblastic leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Helga Thorvaldsdóttir,et al.  Integrative Genomics Viewer , 2011, Nature Biotechnology.

[25]  Maria Grazia Valsecchi,et al.  Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  A. Ferrando,et al.  Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII/ECOG E2993 protocol. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  T. Barbui,et al.  Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). , 2009, Blood.

[28]  B. Schäfer,et al.  Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia , 2008, Leukemia.

[29]  L. Foroni,et al.  Notch-1 Mutations Are Secondary Events in Some Patients with T-Cell Acute Lymphoblastic Leukemia , 2007, Clinical Cancer Research.

[30]  J. Cayuela,et al.  Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data , 2007, Leukemia.

[31]  E. Thiel,et al.  Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. , 2006, Blood.

[32]  J. V. van Dongen,et al.  Vdelta2-Jalpha rearrangements are frequent in precursor-B-acute lymphoblastic leukemia but rare in normal lymphoid cells. , 2004, Blood.

[33]  M Hummel,et al.  Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936 , 2003, Leukemia.

[34]  J. Gabert,et al.  Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects , 2003, Leukemia.

[35]  J. V. van Dongen,et al.  Molecular monitoring of residual disease using antigen receptor genes in childhood acute lymphoblastic leukaemia. , 2002, Best practice & research. Clinical haematology.

[36]  A. Órfão,et al.  Minimal residual disease in leukaemia patients. , 2001, The Lancet. Oncology.

[37]  T. Szczepański,et al.  Cross-lineage T cell receptor gene rearrangements occur in more than ninety percent of childhood precursor-B acute lymphoblastic leukemias: alternative PCR targets for detection of minimal residual disease , 1999, Leukemia.

[38]  M. Kami,et al.  Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood , 1998, The Lancet.

[39]  W. Hop,et al.  Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood , 1998, The Lancet.

[40]  H. Cavé,et al.  Clinical Significance of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia , 1998 .

[41]  J. V. van Dongen,et al.  Unusual immunoglobulin and T-cell receptor gene rearrangement patterns in acute lymphoblastic leukemias. , 1999, Current topics in microbiology and immunology.

[42]  H. Schmetzer,et al.  Minimal residual disease in acute leukemia. , 1991, European journal of cancer.